SYLVANT 400 mg powder for concentrate for solution for infusion
Authorisation EU/1/14/928/002 · EUSA Pharma (Netherlands) B.V.
- Licence holder
- EUSA Pharma (Netherlands) B.V. (all products →)
- Active substance
- Siltuximab
- Clinical trials
- 4 clinical trials →
- Dosage form
- Powder for concentrate for solution for infusion
- Route of administration
- Intravenous use
- ATC codes
- L04AC, L04AC11
- First authorised
- 22/05/2014
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Full application (Article 8(3) of Directive No 2001/83/EC)
Siltuximab: supply and approvals
2 authorised products on the HPRA list contain Siltuximab. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 21 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 21 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 21 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 928. It has been authorised for 12 years (since 22 May 2014). The HPRA list does not say whether it is on sale.
Other medicines with Siltuximab in Ireland
1 other product on the HPRA list contains Siltuximab, from 1 licence holder; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| SYLVANT 100 mg powder for concentrate for solution for infusion | EUSA Pharma (Netherlands) B.V. | Centralised EU authorisation | Not stated |
Other substances in ATC group L04AC
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 10 other active substances share the group L04AC with this product:
Secukinumab (3) · Canakinumab (2) · Sarilumab (2) · Basiliximab (2) · Ixekizumab (2) · Anakinra (1) · Brodalumab (1) · Tocilizumab (1) · RISANKIZUMAB (1) · Spesolimab (1)
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
EUSA Pharma (Netherlands) B.V. holds 5 products on the HPRA list, with 3 different active substances; 0 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.